Louisa Bolm1, Lukas Kaesmann1, Tobias Bartscht2, Steven E Schild3, Dirk Rades4. 1. Departments of Radiation Oncology, University of Lübeck, Lübeck, Germany. 2. Hematoogy & Medical Oncology, University of Lübeck, Lübeck, Germany. 3. Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A. 4. Departments of Radiation Oncology, University of Lübeck, Lübeck, Germany rades.dirk@gmx.net.
Abstract
BACKGROUND/AIM: The role of radio(chemo) therapy for non-metastatic bile duct cancer is not well defined. This study provides additional data for this rare situation. PATIENTS AND METHODS: Data of eight patients receiving radio(chemo)therapy for non-metastatic bile duct cancer were retrospectively analyzed regarding local control, metastases-free survival and overall survival. In addition to the entire cohort, five tumor- or treatment-related factors were investigated: tumor stage, histologic grading, point in time of radio(chemo)therapy, upfront surgery and concurrent chemotherapy. RESULTS: Median overall survival was 37 months. Overall survival rates at 3 and 5 years were 56% and 38%, respectively. Lower histologic grading was significantly associated with better overall survival (p=0.042). Metastases-free survival rates at 3 and 5 years were 38% and 19%, while local control rates were 43% and 21%, respectively. Concurrent radiochemotherapy (vs. radiotherapy alone) resulted in significantly improved local control (p=0.014). CONCLUSION: Radiochemotherapy can achieve promising results in selected patients with non-metastatic bile duct cancer. Copyright
BACKGROUND/AIM: The role of radio(chemo) therapy for non-metastatic bile duct cancer is not well defined. This study provides additional data for this rare situation. PATIENTS AND METHODS: Data of eight patients receiving radio(chemo)therapy for non-metastatic bile duct cancer were retrospectively analyzed regarding local control, metastases-free survival and overall survival. In addition to the entire cohort, five tumor- or treatment-related factors were investigated: tumor stage, histologic grading, point in time of radio(chemo)therapy, upfront surgery and concurrent chemotherapy. RESULTS: Median overall survival was 37 months. Overall survival rates at 3 and 5 years were 56% and 38%, respectively. Lower histologic grading was significantly associated with better overall survival (p=0.042). Metastases-free survival rates at 3 and 5 years were 38% and 19%, while local control rates were 43% and 21%, respectively. Concurrent radiochemotherapy (vs. radiotherapy alone) resulted in significantly improved local control (p=0.014). CONCLUSION: Radiochemotherapy can achieve promising results in selected patients with non-metastatic bile duct cancer. Copyright
Authors: T Todoroki; K Ohara; T Kawamoto; N Koike; S Yoshida; H Kashiwagi; M Otsuka; K Fukao Journal: Int J Radiat Oncol Biol Phys Date: 2000-02-01 Impact factor: 7.038
Authors: Michael A Hughes; Deborah A Frassica; Charles J Yeo; Taylor S Riall; Keith D Lillemoe; John L Cameron; Ross C Donehower; Daniel A Laheru; Ralph H Hruban; Ross A Abrams Journal: Int J Radiat Oncol Biol Phys Date: 2007-02-02 Impact factor: 7.038
Authors: Rosa Autorino; Gian Carlo Mattiucci; Francesco Ardito; Mario Balducci; Francesco Deodato; Gabriella Macchia; Giovanna Mantini; Vincenzo Perri; Andrea Tringali; Maria Antonietta Gambacorta; Luca Tagliaferri; Felice Giuliante; Alessio Giuseppe Morganti; Vincenzo Valentini Journal: Anticancer Res Date: 2016-02 Impact factor: 2.480
Authors: William R Jarnagin; Leyo Ruo; Sarah A Little; David Klimstra; Michael D'Angelica; Ronald P DeMatteo; Raquel Wagman; Leslie H Blumgart; Yuman Fong Journal: Cancer Date: 2003-10-15 Impact factor: 6.860